90 related articles for article (PubMed ID: 33859877)
1. Comparison of metastatic castration-resistant prostate cancer in bone with other sites: clinical characteristics, molecular features and immune status.
Xu Z; Ding Y; Lu W; Zhang K; Wang F; Ding G; Wang J
PeerJ; 2021; 9():e11133. PubMed ID: 33859877
[TBL] [Abstract][Full Text] [Related]
2. Identification of immune cell infiltration pattern and related critical genes in metastatic castration-resistant prostate cancer by bioinformatics analysis.
Fan C; Lu W; Li K; Zhao C; Wang F; Ding G; Wang J
Cancer Biomark; 2021; 32(3):363-377. PubMed ID: 34151837
[TBL] [Abstract][Full Text] [Related]
3. A Circulating Tumor Cell-RNA Assay for Assessment of Androgen Receptor Signaling Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer.
Jan YJ; Yoon J; Chen JF; Teng PC; Yao N; Cheng S; Lozano A; Chu GCY; Chung H; Lu YT; Chen PJ; Wang JJ; Lee YT; Kim M; Zhu Y; Knudsen BS; Feng FY; Garraway IP; Gao AC; Chung LWK; Freeman MR; You S; Tseng HR; Posadas EM
Theranostics; 2019; 9(10):2812-2826. PubMed ID: 31244925
[No Abstract] [Full Text] [Related]
4. Transcriptome Analysis Identifies Tumor Immune Microenvironment Signaling Networks Supporting Metastatic Castration-Resistant Prostate Cancer.
McKinney LP; Singh R; Jordan IK; Varambally S; Dammer EB; Lillard JW
Onco (Basel); 2023 Jun; 3(2):81-95. PubMed ID: 38435029
[TBL] [Abstract][Full Text] [Related]
5. Do the expressions of epithelial-mesenchymal transition proteins, periostin, integrin-α4 and fibronectin correlate with clinico-pathological features and prognosis of metastatic castration-resistant prostate cancer?
Konac E; Kiliccioglu I; Sogutdelen E; Dikmen AU; Albayrak G; Bilen CY
Exp Biol Med (Maywood); 2017 Dec; 242(18):1795-1801. PubMed ID: 28836852
[TBL] [Abstract][Full Text] [Related]
6. Identification and characterization of biomarkers and their functions for docetaxel-resistant prostate cancer cells.
Deng L; Gu X; Zeng T; Xu F; Dong Z; Liu C; Chao H
Oncol Lett; 2019 Sep; 18(3):3236-3248. PubMed ID: 31452801
[TBL] [Abstract][Full Text] [Related]
7. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
8. Identification of SPP1 as an Extracellular Matrix Signature for Metastatic Castration-Resistant Prostate Cancer.
Pang X; Xie R; Zhang Z; Liu Q; Wu S; Cui Y
Front Oncol; 2019; 9():924. PubMed ID: 31620371
[TBL] [Abstract][Full Text] [Related]
9. Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer.
Scher HI; Graf RP; Schreiber NA; McLaughlin B; Lu D; Louw J; Danila DC; Dugan L; Johnson A; Heller G; Fleisher M; Dittamore R
Eur Urol; 2017 Jun; 71(6):874-882. PubMed ID: 27979426
[TBL] [Abstract][Full Text] [Related]
10. Identification of PTPRR and JAG1 as key genes in castration-resistant prostate cancer by integrated bioinformatics methods
Wang JL; Wang Y; Ren GP
J Zhejiang Univ Sci B; 2020 Mar.; 21(3):246-255. PubMed ID: 32133801
[TBL] [Abstract][Full Text] [Related]
11. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES
Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
[TBL] [Abstract][Full Text] [Related]
12. Identification of Key Gene Signatures Associated With Bone Metastasis in Castration-Resistant Prostate Cancer Using Co-Expression Analysis.
Yu Z; Zou H; Wang H; Li Q; Yu D
Front Oncol; 2020; 10():571524. PubMed ID: 33604283
[TBL] [Abstract][Full Text] [Related]
13. Is prostate cancer changing?: evolving patterns of metastatic castration-resistant prostate cancer.
Doctor SM; Tsao CK; Godbold JH; Galsky MD; Oh WK
Cancer; 2014 Mar; 120(6):833-9. PubMed ID: 25302607
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics, treatment pattern, and medical costs associated with metastatic castration-resistant prostate cancer in Chinese tertiary care hospital settings.
Qian Z; Wang Y; Tang Z; Ren D; Wang Z; Chen W; Li Z
J Med Econ; 2019 Aug; 22(8):728-735. PubMed ID: 30913930
[No Abstract] [Full Text] [Related]
15. The identification of key genes and pathways in hepatocellular carcinoma by bioinformatics analysis of high-throughput data.
Zhang C; Peng L; Zhang Y; Liu Z; Li W; Chen S; Li G
Med Oncol; 2017 Jun; 34(6):101. PubMed ID: 28432618
[TBL] [Abstract][Full Text] [Related]
16. Impact of nadir PSA level and time to nadir during initial androgen deprivation therapy on prognosis in patients with metastatic castration-resistant prostate cancer.
Hamano I; Hatakeyama S; Narita S; Takahashi M; Sakurai T; Kawamura S; Hoshi S; Ishida M; Kawaguchi T; Ishidoya S; Shimoda J; Sato H; Mitsuzuka K; Tochigi T; Tsuchiya N; Arai Y; Habuchi T; Ohyama C
World J Urol; 2019 Nov; 37(11):2365-2373. PubMed ID: 30729312
[TBL] [Abstract][Full Text] [Related]
17. Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database.
Delanoy N; Hardy-Bessard AC; Efstathiou E; Le Moulec S; Basso U; Birtle A; Thomson A; Krainer M; Guillot A; De Giorgi U; Hasbini A; Daugaard G; Bahl A; Chowdhury S; Caffo O; Beuzeboc P; Spaeth D; Eymard JC; Fléchon A; Alexandre J; Helissey C; Butt M; Priou F; Lechevallier É; Deville JL; Goupil MG; Morales R; Thiery-Vuillemin A; Gavrikova T; Barthelemy P; Sella A; Fizazi K; Baciarello G; Fererro JM; Laguerre B; Verret B; Hans S; Oudard S
Eur Urol Oncol; 2018 Dec; 1(6):467-475. PubMed ID: 31158090
[TBL] [Abstract][Full Text] [Related]
18. Identification of Key Biomarkers and Potential Molecular Mechanisms in Renal Cell Carcinoma by Bioinformatics Analysis.
Li F; Guo P; Dong K; Guo P; Wang H; Lv X
J Comput Biol; 2019 Nov; 26(11):1278-1295. PubMed ID: 31233342
[No Abstract] [Full Text] [Related]
19. Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Hansen AR; Tannock IF; Templeton A; Chen E; Evans A; Knox J; Prawira A; Sridhar SS; Tan S; Vera-Badillo F; Wang L; Wouters BG; Joshua AM
Oncologist; 2019 Sep; 24(9):1188-1194. PubMed ID: 30952818
[TBL] [Abstract][Full Text] [Related]
20. Analysis of genomics and immune infiltration patterns of epithelial-mesenchymal transition related to metastatic breast cancer to bone.
Liu S; Song A; Wu Y; Yao S; Wang M; Niu T; Gao C; Li Z; Zhou X; Huo Z; Yang B; Liu Y; Wang Y
Transl Oncol; 2021 Feb; 14(2):100993. PubMed ID: 33333372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
